The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1829-1835

  Lau, Katharina ^a   Lorbeer, Roberto ^a   Haring, Robin ^b   Schmidt, Carsten O ^a   Wallaschofski, Henri ^b   Nauck, Matthias ^b   John, Ulrich ^c   Baumeister, Sebastian E ^a   Völzke, Henry ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b Laboratory Medicine   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

blood pressure; fatty liver disease; hypertension; longitudinal study

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; FOLLOW UP; GERMANY; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 77955853531     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c211b     Document Type: Article

References (23)

1. Targher G. Nonalcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med 2007; 24:1-6.
2. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240.
3. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study.J Hepatol 2001; 35:531-537.
4. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Nonalcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353-358.
5. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104:861-867.
6. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53:1020-1023.
7. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19:646-653.
8. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13:6419-6424.
9. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22:1086-1091.
10. Friies-Liby Iea. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gatroenterol 2004; 39:864-869.
11. Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Nonalcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007; 13:2193-2198.
12. Caballeria L, Auladell MA, Toran P, Pera G, Miranda D, Aluma A, et al. Risk factors associated with nonalcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterol 2008; 8:44.
13. Adams LA, Angulo P. Recent concepts in nonalcoholic fatty liver disease. Diabet Med 2005; 22:1129-1133.
14. Caballeria L, Auladell MA, Toran P, Miranda D, Aznar J, Pera G, et al. Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterol 2007; 7:41.
15. Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, Hense HW, et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24:293-299.
16. Haring R, Alte D, Volzke H, Sauer S, Wallaschofski H, John U, et al. Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol 2009; 62:252-260.
17. Ludemann J,PiekM, Wood WG, MeyerS, GreinerB,John U,et al. Methods for quality assurance of medical examination in epidemiological field studies: The 'Study of Health in Pomerania' (SHIP). Gesundheitswesen 2000; 62:234-243.
18. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11:1848-1853.
19. Volzke H, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007; 56:594-595.
20. Baumeister SE, Volzke H, Marschall P, John U, Schmidt CO, Flessa S, et al. Impact of fatty liver disease on healthcare utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134:85-94.
21. Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health (Lond, Engl) 2009; 5:191-203.
22. Volzke H, Nauck M, Rettig R, Dorr M, Higham C, Brabant G, et al. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 2009; 161:705-713.
23. Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010; 33:45-53.